XBiotech Inc
For the period ended Mar 31, 2024. Filed May 10, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 10, 2024
XBIT$1.89+1.1%Stored close · as of Nov 6, 2026
Contents
Consolidated Statements of Operations for the Three Months Ended March 31, 2024 (unaudited) and 2023 (unaudited)
(in thousands, except share and per share data)
| Three Months Ended March 31, | ||
|---|---|---|
| 2024 | 2023 | |
| (unaudited) | (unaudited) | |
| Operating expenses: | ||
| Research and development | $9,825 | $6,230 |
| General and administrative | 1,028 | 915 |
| Total operating expenses | 10,853 | 7,145 |
| Loss from operations | (10,853) | (7,145) |
| Other income : | ||
| Interest income | 2,658 | 2,779 |
| Other (expense) income | (200) | 130 |
| Foreign exchange (loss) gain | (1,582) | 383 |
| Total other income | 876 | 3,292 |
| Loss before income taxes | (9,977) | (3,853) |
| Income tax expense | (25) | (37) |
| Net loss | $(10,002) | $(3,816) |
| Net loss per share—basic and diluted | $(0.33) | $(0.13) |
| Shares used to compute basic and diluted net loss per share | 30,443,973 | 30,439,275 |
See accompanying notes to unaudited condensed consolidated financials statements.
Condensed Consolidated Statements of Comprehensive Loss (unaudited)
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.